UK gets closer to formulating wider societal benefit pricing mechanism
This article was originally published in Scrip
Executive Summary
The UK is getting closer to coming up with a way to link the price of a new drug to the benefits it offers, not only to patients, but crucially to wider society. Although some pricing and reimbursement authorities look at a drug's wider societal benefits, no one has yet come up with a way of concretely linking them to a drug's price. So if the UK gets this right, whatever it comes up with could have a big impact in many other cash-strapped markets wrestling with limited drugs budgets and soaring medicine costs.